Invivyd Inc. (IVVD NASDAQ) stock market data APIs
$1.5727
-0.1(-6.4%)
as of November 7, 2025
Try our APIs with
free plan!
Invivyd Inc. Financial Data Overview
Price chart is built with
Anychart
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.5727
Open
1.474
High
1.6006
Low
1.3739
52 wk Range
0.355-2.74
Market Cap
340 M
Shares Outstanding
214 M
Revenue
50 039 K
EPS
-0.06
Beta
0.642
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Invivyd Inc. data using free add-ons & libraries
Get Invivyd Inc. Fundamental Data
Invivyd Inc. Fundamental data includes:
- Net Revenue: 50 039 K
- EBITDA: -60 544 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Invivyd Inc. News
New
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalen...
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago. These ...
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical...
Invivyd Gets FDA Clearance To Start Clinical Trials For COVID-19 Antibody VYD2311
(RTTNews) - Invivyd, Inc. (IVVD) Monday announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for VYD2311, a vaccine alternati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
